Hematology | Clinical

R/R Multiple Myeloma: Review of the CARTITUDE Trial

December 23, 2020

Recent updates from the ASH 2020 annual meeting on the phase 1b/2 CARTITUDE-1 trial for relapsed/refractory multiple myeloma.

Moving Forward in the Management of Acute GvHD

December 23, 2020

Expert physicians discuss the rationale behind the clinical use of JAK inhibitors in acute GvHD (graft-versus-host disease), and provide an overview of recent clinical trial data for this treatment approach.

A 75-Year-Old Woman With Multiple Myeloma

December 22, 2020

Saad Usmani, MD, presents a case of a 75-year-old woman with multiple myeloma.

FDA Biologics License Application for JZP-458 Initiated for 2 Leukemia Indications

December 21, 2020

The submission of a Biologics License Application has been initiated seeking approval of JZP-458 as a part of a multi-agent chemotherapy regimen as treatment of adult and pediatric patients with acute lymphoblastic leukemia or lymphoblastic lymphoma who developed hypersensitivity or silent inactivation to E. coli-derived asparaginases.

FDA Approves New Rituximab Biosimilar in NHL, CLL, and Other Hematologic Malignancies

December 18, 2020

The FDA granted approval to rituximab-arrx, a biosimilar to rituximab as treatment of adult patients with non-Hodgkin lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis, and microscopic polyangiitis.

Different Staging, Risk Stratification, and Treatment Methods for Acute GVHD

December 17, 2020

During a Targeted Oncology Case Based Peer Perspectives event, Miguel-Angel Perales, MD, discussed testing for risk stratification and treatment of graft-versus-host-disease based on the case of a 48-year-old man.

2020 ASH Recap: Hematologists Review Most Impactful Data Across Hematologic Malignancies

December 16, 2020

Following the 2020 ASH Annual Meeting, a number of hematology experts shared their insights on the most important data presented during the meeting with Targeted Oncology.

Ibrutinib Plus Rituximab Data Surprising in Waldenstrom’s Macroglobulinemia

December 15, 2020

Christian Buske, MD, discusses surprising findings from the 5-Year follow-up of a randomized phase 3 trial in patients with Waldenström’s macroglobulinemia receiving of ibrutinib plus rituximab or placebo plus rituximab.

Early-Phase Study Shows Activity and Safety for TRPH-222 in R/R NHL

December 09, 2020

A phase 1 trial showed early signals of tolerability and efficacy in patients with relapsed or refractory B-cell non-Hodgkin lymphoma with TRPH-222 across dose levels.

Benefit From MURANO Trial in CLL Sustained With Subsequent Therapy

December 09, 2020

An analysis from the MURANO trial showed that venetoclax in combination with rituximab led to a more than doubling of time to next treatment compared with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.